CVR number 29513503
Industry 86.9090 Other human health activities

SVANELYKKE ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...
Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  3.3% 3.0% 10.2% 9.3% 5.2%  
Credit score (0-100)  56 57 23 26 42  
Credit rating  BBB BBB BB BB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  333 666 1,714 953 296  
Gross profit  75.2 333 76.8 874 51.1  
EBITDA  75.2 333 76.8 65.6 0.5  
EBIT  57.1 333 76.8 65.6 0.5  
Pre-tax profit (PTP)  36.3 332.7 76.8 65.6 0.5  
Net earnings  36.3 332.7 76.8 65.6 0.5  
Pre-tax profit without non-rec. items  36.3 333 76.8 65.6 0.5  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Tangible assets total  1,347 1,347 0.0 0.0 139  
Shareholders equity total  71.0 404 480 546 547  
Interest-bearing liabilities  1,354 1,179 0.0 0.9 0.0  
Balance sheet total (assets)  1,463 1,583 480 553 553  
Net Debt  1,239 961 -143 -295 -120  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  333 666 1,714 953 296  
Net sales growth  148.8% 99.7% 157.6% -44.4% -68.9%  
Gross profit  75.2 333 76.8 874 51.1  
Gross profit growth  0.0% 342.4% -76.9% 1,038.7% -94.2%  
Employees  0 0 0 0 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,463 1,583 480 553 553  
Balance sheet change%  5.4% 8.2% -69.6% 15.1% 0.0%  
Added value  75.2 332.7 76.8 65.6 0.5  
Added value %  22.6% 50.0% 4.5% 6.9% 0.2%  
Investments  -36 0 -1,347 0 139  
Net sales trend  1.0 2.0 3.0 -1.0 -2.0  
EBIT trend  1.0 2.0 3.0 4.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  22.6% 50.0% 4.5% 6.9% 0.2%  
EBIT %  17.1% 50.0% 4.5% 6.9% 0.2%  
EBIT to gross profit (%)  76.0% 100.0% 100.0% 7.5% 1.0%  
Net Earnings %  10.9% 50.0% 4.5% 6.9% 0.2%  
Profit before depreciation and extraordinary items %  16.3% 50.0% 4.5% 6.9% 0.2%  
Pre tax profit less extraordinaries %  10.9% 50.0% 4.5% 6.9% 0.2%  
ROA %  4.0% 21.8% 7.4% 12.7% 0.1%  
ROI %  4.1% 22.1% 7.4% 12.8% 0.1%  
ROE %  68.6% 140.2% 17.4% 12.8% 0.1%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  4.9% 20.8% 100.0% 98.7% 98.8%  
Relative indebtedness %  417.5% 231.3% 0.0% 0.7% 2.2%  
Relative net indebtedness %  382.8% 198.5% -8.3% -30.3% -38.1%  
Net int. bear. debt to EBITDA, %  1,647.5% 288.8% -185.8% -449.0% -23,353.7%  
Gearing %  1,908.1% 292.1% 0.0% 0.2% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  1.5% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.2 0.7 0.0 79.6 62.7  
Current Ratio  0.2 0.7 0.0 79.6 62.7  
Cash and cash equivalent  115.7 218.3 142.6 295.6 119.6  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  34.7% 35.4% 28.0% 58.0% 139.7%  
Net working capital  -426.5 -124.8 480.4 546.1 407.4  
Net working capital %  -128.0% -18.8% 28.0% 57.3% 137.5%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 296  
Added value / employee  0 0 0 0 1  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 1  
EBIT / employee  0 0 0 0 1  
Net earnings / employee  0 0 0 0 1